Option chain shows key data for OWC Pharmaceutical's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for OWC Pharmaceutical.

OWC Pharmaceutical (OTC:OWCP) Stock, Option Chain

OWC Pharmaceutical Research Corp is a medical cannabis research and development company. The firm through its subsidiary researches and develops cannabis-based products and treatments specifically designed for multiple myeloma, psoriasis, fibromyalgia, post-traumatic stress disorder (PTSD), migraine, sexual function and skin disorders. It also provides consulting services to governmental and private entities to assist them with developing and implementing tailor-made medical cannabis program.

Cannabis

News

OWCP

OWC Pharmaceutical Research Corp. (OTCQB: OWCP) has inked a distribution deal with Florida-based cannabis and hemp corporation 

OWC To Distribute Products In The Americas Through Florida&#39;s Can IT

Penny Stocks

Markets

APHA

AQSP

BMMJ

CNBS

MASSIVE INTERACTIVE NV by Massive Interactive, Inc.

HUGE

JUSHI HLDGS INC CL B by Jushi Holdings Inc.

JUSHF

RWBYF

SAMA

THCX

VREOF

YOLO

TSX:APHA

CSE:BAMM

CSE:VCAN

CSE:RWB

TSX:WEED

CSE:HUGE

CSE:VREO

Cannabis stocks, and overall markets, closed the week in the green, as cannabis companies got into their earnings season.

The Week In Cannabis: Strong Earnings, Stocks In Green, Investments And Divestments

Isiah Thomas-led One World Pharma Looks To Hemp As Viable Alternative To Plastic

OWC PHARMS RESEARCH CORP by OWC Pharmaceutical Research Corp.

OWC Pharmaceutical Research Corp

PLTR

Pray.com And Palantir Join Forces To Enhance Multilingual Faith-Based Content Using Advanced AI Technology

B of A Securities analyst Tazeen Ahmad initiates coverage on KalVista Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALV#NASDAQ">KALV</a>) with a Buy rating and announces Price Target of $22.

Price Target

Initiation

Analyst Ratings

KALV

B of A Securities Initiates Coverage On KalVista Pharma with Buy Rating, Announces Price Target of $22

Rosenblatt analyst Hans Mosesmann maintains Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) with a Buy and maintains $250 price target.

Rosenblatt Maintains Buy on Micron Technology, Maintains $250 Price Target

Beyond the strategic partnership with Sysco, Square also announced new features to help restaurants run their businesses easily and efficiently. These features are currently rolling out to sellers, with full availability in early 2025.

Square Enters New Partnership With Sysco

B of A Securities analyst Saurabh Pant maintains Baker Hughes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>) with a Buy and raises the price target from $42 to $48.

B of A Securities Maintains Buy on Baker Hughes, Raises Price Target to $48

Citigroup analyst Paul Lejuez initiates coverage on On Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONON#NYSE">ONON</a>) with a Neutral rating and announces Price Target of $65.

ONON

Citigroup Initiates Coverage On On Holding with Neutral Rating, Announces Price Target of $65

Mizuho analyst John Baumgartner maintains Nomad Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOMD#NYSE">NOMD</a>) with a Outperform and lowers the price target from $28 to $24.

NOMD

Mizuho Maintains Outperform on Nomad Foods, Lowers Price Target to $24

Barry will continue to report to ICON's Chief Executive Officer, Steve Cutler.

Management

ICLR

ICON Appoints Barry Balfe As COO

Citigroup analyst Paul Lejuez initiates coverage on Academy Sports (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASO#NASDAQ">ASO</a>) with a Buy rating and announces Price Target of $65.

Citigroup Initiates Coverage On Academy Sports with Buy Rating, Announces Price Target of $65

<ul>
<li>Oklo and Switch have signed one of the largest corporate power agreements in history, a 12-gigawatts non-binding Master Power Agreement.</li>
<li>This milestone agreement demonstrates a shared commitment to advancing sustainable energy solutions, supporting data center growth, and driving industry-wide decarbonization.</li>
<li>Oklo's Aurora powerhouses will provide reliable, clean energy for Switch's cutting-edge AI, cloud, and enterprise data center infrastructure.</li>
</ul>

OKLO

Oklo And Switch Partner To Deploy 12 GW Of Advanced Nuclear Power

Adjusted operating profit is now expected to range between down 4 percent and down 2 percent in constant currency, compared to the previous range of between down 2 percent and flat in constant currency, reflecting higher investment levels.&nbsp;

Guidance

General Mills Revises FY25 Adjusted EPS Outlook Range To Down 3% To Down 1% In Constant Currency, Compared To Previous Range Of Down 1% To Up 1%

Biotech

Health Care

General

ORKA

Oruka Therapeutics Announced That It Is Expected To Be Added To The Nasdaq Biotechnology Index (NBI), Oruka's Addition Will Become Effective Prior To Market Open On December 23

ABM Sees FY25 Adjusted EPS Outlook Of $3.60-$3.80 Vs. $3.66 Est., Adjusted EBITDA Margin Of 6.3% to 6.5%

Citigroup analyst Steven Zaccone upgrades Ollie's Bargain Outlet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLLI#NASDAQ">OLLI</a>) from Sell to Buy and raises the price target from $64 to $133.

Upgrades

OLLI

Citigroup Upgrades Ollie's Bargain Outlet to Buy, Raises Price Target to $133

Baird analyst Andrew Wittmann downgrades Fluor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLR#NYSE">FLR</a>) from Outperform to Neutral and raises the price target from $54 to $58.

Downgrades

Baird Downgrades Fluor to Neutral, Raises Price Target to $58

. Earlier, in November 2020, the U.S. Food and Drug Administration (FDA) also granted orphan drug designation to mitapivat for sickle cell disease.

AGIO

The European Commission Has Adopted A Positive Decision For The Designation Of Agios Pharmaceuticals' Mitapivat As An Orphan Medicinal Product For Sickle Cell Disease

Needham analyst Laura Martin maintains Outbrain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OB#NASDAQ">OB</a>) with a Buy and raises the price target from $6 to $9.

Needham Maintains Buy on Outbrain, Raises Price Target to $9

Biomarker data from CARE study characterizing cenerimod's mechanism of action in systemic lupus erythematosus also published in the Annals of the Rheumatic Diseases

VTRS

Viatris Announces Publication Of Phase 2b CARE Study Results For Cenerimod, Demonstrating Efficacy In Moderate-To-Severe Lupus

Organic net sales results in the second half are expected to include a 1-point headwind from the reversal of timing-related benefits in the second quarter.

General Mills Now Targets Lower End Of FY25 Organic Net Sales Outlook Range Of Flat To Up 1%, Due To Increased Promotional Investment

ABM Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABM#NYSE">ABM</a>) reported quarterly earnings of $0.90 per share which beat the analyst consensus estimate of $0.87 by 3.45 percent. The company reported quarterly sales of $2.177 billion which beat the analyst consensus estimate of $2.079 billion by 4.71 percent. This is a 4.03 percent increase over sales of $2.093 billion the same period last year.

Comments

OWC Pharmaceutical

OWC Pharmaceutical (OWCP) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga